Novel Technologies for Treating Neovascular Age-Related Macular Degeneration

WebMD Global requires every individual in a position to control educational content to disclose all financial relationships with ineligible companies that have occurred within the past 24 months. Ineligible companies are organizations whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.

All relevant financial relationships for anyone with the ability to control the content of this educational activity are listed below and have been mitigated. Others involved in the planning of this activity have no relevant financial relationships.

Moderator

Dante J. Pieramici, MD

Partner
California Retina Consultants
Director
California Retina Research Foundation
Santa Barbara, California, United States

Disclosures

Dante J. Pieramici, MD, has the following relevant financial relationships:
Consultant or advisor for: Adverum Bio; Arrowhead; Gemini; Genentech; NGM; Opthea; Regeneron; Regenx Bio; Unity
Research funding from: 4DMT; Adverum; Apellis; Clearside; Genentech; Kodiac; Ocular Therapeutic; Opthea; Regenx Bio; Stealth

Faculty

Veeral Sheth, MD, MBA

Clinical Assistant Professor
University of Illinois Chicago
Director of Clinical Research
University Retina and Macula Associates
Chicago, Illinois, United States

Disclosures

Veeral Sheth, MD, MBA, has the following relevant financial relationships:
Consultant or advisor for: Alimera; Apellis; EyePoint; Genentech; Graybug; IvericBio; Novartis; Regeneron
Speaker or member of speakers bureau for: Alimera; Apellis; Genentech
Research funding from: Alimera Sciences; Allergan; Chengdu Kanghong; Eyepoint; Genentech; Gyroscope; Ionis; IvericBio; NGM Biopharmaceuticals; Novartis; Opthea; Outlook; Oxurion; Recens Medical; Regeneron; Regenxbio; Roche; SalutarisMD; SamChungDang; Santen

Armin Wolf, MD

Professor of Ophthalmology
Director
Department of Ophthalmology
University of Ulm
Ulm, Germany

Disclosures

Armin Wolf, MD, has the following relevant financial relationships:
Consultant or advisor for: Apellis; Bayer; Novartis; Oertli; Roche; Zeiss
Speaker or member of speakers bureau for: AbbVie; Apellis; Bayer; Novartis; Oertli; Roche; Zeiss
Research funding from: Bayer; Novartis; Roche

Editor

Katherine Carpenter, PhD

Medical Education Director, WebMD Global, LLC

Disclosures

Katherine Carpenter, PhD, has the following relevant financial relationship:
Advisor or consultant for: Eisai (former); GW Pharmaceuticals (former)

Compliance Reviewer

Susan L. Smith, MN, PhD

Associate Director, Accreditation and Compliance

Disclosures

Susan L. Smith, MN, PhD, has no relevant financial relationships.